Meiji Yasuda Asset Management Co Ltd. Has $473,000 Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Meiji Yasuda Asset Management Co Ltd. reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,145 shares of the company’s stock after selling 99 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in IDEXX Laboratories were worth $473,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in IDXX. Segall Bryant & Hamill LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at approximately $8,600,000. KLP Kapitalforvaltning AS acquired a new stake in shares of IDEXX Laboratories in the fourth quarter worth $15,876,000. American Century Companies Inc. increased its position in IDEXX Laboratories by 30.9% during the fourth quarter. American Century Companies Inc. now owns 809,814 shares of the company’s stock worth $334,810,000 after acquiring an additional 191,385 shares during the period. Mizuho Securities USA LLC raised its stake in IDEXX Laboratories by 45.4% during the 4th quarter. Mizuho Securities USA LLC now owns 7,761 shares of the company’s stock valued at $3,209,000 after purchasing an additional 2,424 shares during the last quarter. Finally, Quantbot Technologies LP boosted its holdings in IDEXX Laboratories by 1,870.5% in the 4th quarter. Quantbot Technologies LP now owns 13,301 shares of the company’s stock valued at $5,499,000 after purchasing an additional 12,626 shares during the period. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $422.54 on Friday. The stock has a market capitalization of $34.25 billion, a price-to-earnings ratio of 39.60, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The business’s fifty day moving average price is $437.13 and its two-hundred day moving average price is $443.72. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $548.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research reports. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Bank of America boosted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday. Barclays boosted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Finally, Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.